DprE1 inhibitors – a prospective target for development of antituberculosis drugs
The article reviews and analyzes 63 scientific publications devoted to new classes of antituberculosis drugs – DprE1 inhibitors. Currently, compounds BTZ-043, PBTZ-169 (makozinone), TBA-7371 and OPC-167832 are tested at different stages of clinical trials. DprE1 inhibitors are promising drugs with ant...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
New Terra Publishing House
2022-06-01
|
| Series: | Туберкулез и болезни лёгких |
| Subjects: | |
| Online Access: | https://www.tibl-journal.com/jour/article/view/1644 |